CL2017000659A1 - Inhibidores de histona desmetilasa - Google Patents
Inhibidores de histona desmetilasaInfo
- Publication number
- CL2017000659A1 CL2017000659A1 CL2017000659A CL2017000659A CL2017000659A1 CL 2017000659 A1 CL2017000659 A1 CL 2017000659A1 CL 2017000659 A CL2017000659 A CL 2017000659A CL 2017000659 A CL2017000659 A CL 2017000659A CL 2017000659 A1 CL2017000659 A1 CL 2017000659A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer
- compositions
- histone demethylase
- compounds
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
<p>La presente invención se relaciona en general con composiciones y métodos para tratar cáncer y enfermedad neoplásica. Se proporcionan aquí compuestos derivados de pirido[3,4-d]pirimidin-4-ona sustituidos y omposiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones objeto son útiles para inhibición de histona desmetilasa. Adicionalmente, los compuestos y composiciones objeto son útiles para el tratamiento de cáncer, tal como cáncer de próstata, cáncer de mama, cáncer de vejiga, cáncer de pulmón y/o melanoma y similares.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051691P | 2014-09-17 | 2014-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000659A1 true CL2017000659A1 (es) | 2018-05-11 |
Family
ID=55525128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000659A CL2017000659A1 (es) | 2014-09-17 | 2017-03-17 | Inhibidores de histona desmetilasa |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US9643965B2 (es) |
| EP (2) | EP3453710B1 (es) |
| JP (1) | JP6552608B2 (es) |
| KR (1) | KR20170048591A (es) |
| CN (1) | CN107205391A (es) |
| AU (1) | AU2015317806A1 (es) |
| BR (1) | BR112017005511A2 (es) |
| CA (1) | CA2961610A1 (es) |
| CL (1) | CL2017000659A1 (es) |
| CO (1) | CO2017003538A2 (es) |
| EA (1) | EA201790603A1 (es) |
| EC (1) | ECSP17023551A (es) |
| ES (1) | ES2910226T3 (es) |
| IL (1) | IL251179A0 (es) |
| MX (1) | MX2017003466A (es) |
| SG (1) | SG11201702147TA (es) |
| WO (1) | WO2016044429A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2970211T (lt) | 2013-03-15 | 2017-10-25 | Quanticel Pharmaceuticals Inc | Histono demetilazės inhibitoriai |
| SG11201702147TA (en) | 2014-09-17 | 2017-04-27 | Celgene Quanticel Res Inc | Histone demethylase inhibitors |
| WO2017161012A1 (en) | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| MA45887B1 (fr) | 2016-11-28 | 2021-04-30 | Teijin Pharma Ltd | Cristal de dérivé de pyrido [3, 4-d] pyrimidine ou son solvate |
| JP2020523282A (ja) | 2017-03-29 | 2020-08-06 | パデュー リサーチ ファウンデイション | キナーゼネットワークの阻害剤およびその使用 |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| CN115368252B (zh) * | 2022-09-19 | 2024-01-12 | 西北农林科技大学 | 一种4-胺基酚类衍生物及应用 |
| CN116253712A (zh) * | 2023-03-27 | 2023-06-13 | 昆山市第一人民医院 | 5,6,7-三甲氧基-2,3-二氢喹啉类化合物、药物组合物及用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003033472A1 (fr) * | 2001-10-17 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes |
| US20040009981A1 (en) | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| JP2007501854A (ja) * | 2003-05-27 | 2007-02-01 | ファイザー・プロダクツ・インク | 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド［３，４−ｄ］ピリミジン類 |
| US7544677B2 (en) * | 2004-08-23 | 2009-06-09 | Merck & Co., Inc. | Inhibitors of Akt activity |
| FR2876103B1 (fr) | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| WO2008033747A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| TW200922590A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
| JP5552608B2 (ja) | 2012-04-27 | 2014-07-16 | 株式会社ソフイア | 遊技機 |
| CN107434803B (zh) | 2012-10-02 | 2020-05-05 | 吉利德科学公司 | 组蛋白去甲基化酶抑制剂 |
| SI2934145T1 (en) | 2012-12-19 | 2018-03-30 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2014100818A1 (en) | 2012-12-21 | 2014-06-26 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| JP6320506B2 (ja) | 2013-03-12 | 2018-05-09 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| EP2968537A1 (en) | 2013-03-15 | 2016-01-20 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| LT2970211T (lt) | 2013-03-15 | 2017-10-25 | Quanticel Pharmaceuticals Inc | Histono demetilazės inhibitoriai |
| AU2015279719B2 (en) | 2014-06-25 | 2019-03-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| SG11201702147TA (en) * | 2014-09-17 | 2017-04-27 | Celgene Quanticel Res Inc | Histone demethylase inhibitors |
| WO2017161012A1 (en) | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
-
2015
- 2015-09-16 SG SG11201702147TA patent/SG11201702147TA/en unknown
- 2015-09-16 KR KR1020177009917A patent/KR20170048591A/ko not_active Withdrawn
- 2015-09-16 US US14/855,950 patent/US9643965B2/en active Active
- 2015-09-16 BR BR112017005511A patent/BR112017005511A2/pt not_active Application Discontinuation
- 2015-09-16 AU AU2015317806A patent/AU2015317806A1/en not_active Abandoned
- 2015-09-16 EP EP18181949.1A patent/EP3453710B1/en active Active
- 2015-09-16 ES ES15842574T patent/ES2910226T3/es active Active
- 2015-09-16 MX MX2017003466A patent/MX2017003466A/es unknown
- 2015-09-16 CN CN201580061425.6A patent/CN107205391A/zh active Pending
- 2015-09-16 CA CA2961610A patent/CA2961610A1/en not_active Abandoned
- 2015-09-16 EA EA201790603A patent/EA201790603A1/ru unknown
- 2015-09-16 EP EP15842574.4A patent/EP3193601B1/en active Active
- 2015-09-16 JP JP2017514615A patent/JP6552608B2/ja not_active Expired - Fee Related
- 2015-09-16 WO PCT/US2015/050432 patent/WO2016044429A1/en active Application Filing
-
2017
- 2017-03-15 IL IL251179A patent/IL251179A0/en unknown
- 2017-03-17 CL CL2017000659A patent/CL2017000659A1/es unknown
- 2017-04-12 CO CONC2017/0003538A patent/CO2017003538A2/es unknown
- 2017-04-17 EC ECIEPI201723551A patent/ECSP17023551A/es unknown
- 2017-05-05 US US15/588,561 patent/US10112940B2/en active Active
-
2018
- 2018-09-20 US US16/137,219 patent/US10611763B2/en active Active
-
2020
- 2020-02-14 US US16/790,878 patent/US10815234B2/en active Active
- 2020-09-21 US US17/026,763 patent/US11535616B2/en active Active
-
2022
- 2022-11-03 US US17/980,291 patent/US12172998B2/en active Active
-
2024
- 2024-11-01 US US18/935,237 patent/US20250066355A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016003350A1 (es) | Inhibidores de demetilasa-1 especifica de lisina | |
| CL2017000659A1 (es) | Inhibidores de histona desmetilasa | |
| CL2017000521A1 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| CR20150368A (es) | Inhibidores de histona desmetilasa | |
| CO2017000359A2 (es) | Compuestos derivados de piridina sustituidos como inhibidores de histonas desmetilasa | |
| MX2017000170A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
| MX2020010496A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
| ECSP17006821A (es) | Inhibidores de la desmetilasa-1 específica de la lisina | |
| CL2017000643A1 (es) | Inhibidores de histona desmetilasa | |
| MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
| ECSP17022542A (es) | Inhibidores de la histona desmetilasa | |
| MX2018005515A (es) | Derivados de 1,4-dicarbonil-piperidilo. |